Gastrointestinal infections, which are caused primarily by pathogenic bacteria, remain a significant global health challenge. Their resilience is reinforced by various physical, biological, and biopharmaceutical barriers that complicate conventional therapeutic strategies. This review delves into the intricate landscape of managing these infections, addressing microbiota imbalances, the emergence of multidrug‐resistant strains, and the impact of dysbiosis and antibiotic overuse. Faced with these challenges, traditional therapies often fail, which is hindered by low bioavailability, prolonged regimens, and a growing risk of resistance. In this context, nanotechnology applied to antimicrobial peptides (AMPs) has emerged as a promising solution to enhance their stability and targeted delivery. Through a critical approach, diverse nanocarriers and their efficacy against intestinal pathogens are evaluated both in vitro and in vivo. This review advocates for intensified research on the encapsulation and functionalization of AMPs, envisioning their potential to redefine the control of intestinal infections on a global scale.
Antimicrobial peptides (AMPs) have re-emerged as promising anti-infective agents, particularly against multidrug-resistant bacteria; however, their therapeutic development remains constrained by proteolytic degradation, host cell toxicity, and rapid systemic clearance. Rather than focusing solely on sequence discovery, recent efforts have shifted toward structural and supramolecular modification strategies aimed at improving stability, selectivity, and pharmacological performance. This review critically analyzes intramolecular modifications—including phosphorylation, glycosylation, acetylation, methylation, and backbone cyclization—that modulate peptide conformation and resistance to enzymatic degradation. In parallel, extramolecular approaches such as PEGylation, lipidation, and conjugation to antibiotics, siderophores, or antibodies are examined in the context of enhanced targeting and prolonged bioavailability. Particular emphasis is placed on localized delivery systems, including hydrogels, polymeric films, and nanofibrous scaffolds, which enable spatially controlled administration and mitigate systemic exposure. By integrating evidence from ex vivo and in vivo infection models, this work delineates the translational potential and remaining bottlenecks of chemically engineered AMP platforms for skin and soft tissue infections.